Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) has shared an announcement.
Shenzhen Hepalink Pharmaceutical Group expects its net profit attributable to shareholders for 2025 to decline sharply year on year to approximately RMB284 million–RMB377 million, down about 41.71% to 56.09% from 2024, reflecting the absence of last year’s substantial one-off investment income and the impact from an associate’s weaker-than-expected R&D progress. However, net profit after excluding non-recurring items is forecast to rise significantly to RMB362 million–RMB460 million, an increase of roughly 42.78% to 81.43%, underscoring stronger underlying operations driven by robust growth in the group’s global heparin finished dose and enoxaparin businesses, which are reinforcing Hepalink’s competitive position despite the drag from non-recurring factors.
The most recent analyst rating on (HK:9989) stock is a Hold with a HK$5.50 price target. To see the full list of analyst forecasts on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H stock, see the HK:9989 Stock Forecast page.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company focused on heparin and related anticoagulant products, with a growing global business in heparin finished doses. The group’s enoxaparin finished dose products have been gaining market share worldwide, supported by steady sales growth across multiple regions and an expanding international footprint.
Average Trading Volume: 981,870
Technical Sentiment Signal: Buy
Current Market Cap: HK$18.4B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.